Hepatocyte-specific deletion of Alkbh5 improves glucose tolerance and mitigates metabolic dysfunction-associated fatty liver disease (MAFLD) in obesity by inhibiting GCGR–cyclic adenosine monophosphate (cAMP) and EGFR–PI3K–AKT–mTORC1 signaling. Here, ALKBH5 is linked to obesity disorder.